Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome cardvic...you can find all that on this page
https://www.otcmarkets.com/stock/OMHE/profile
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
OMHE_PPS_Rising_Applied_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
$OMHE_Rising_ALERT_1c_to_4c_in_Last_4_Weeks
11/14/2017 MMJ Medicine Development and Future Plans Updates News
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
OMHE_with_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
$OMHE_ALERT_1c_to_4c_in_Last_4_Weeks
OMHE_PPS_rose_from_1c_to_4c_i.e.300%_rise_in_LAST_4_WEEKS
11/14/2017 MMJ Medicine Development and Future Plans Updates News
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks******
OMHE_is_Adding_$7Million_in_Rev_By_Supplying_OverTheCounter_MJ_Ointments_to_Doctors, Clinics & Hospitals
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
FDA_will_Approve_OMHE’s_CBD_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1
OMHE_Rev~$20Mil_ShareRestruc_QBuplist_MMJcultivation_OverTCntrCBDmedicines_NEXT
$OMHE_ALERT!!!!_1c_to_4c_in_Last_4_Weeks
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
OMHE_PPS@4c_Supplying_OverTheCounter_MJ_Ointments_to_Doctors_Clinics_Hospitals
$OMHE_Rising_1c_to_4c_in_Last_4_Weeks
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
$OMHE Rising: 1c to 4c in Last 4_Weeks
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
$OMHE Rising: 1c to 4c in Last 4_Weeks
OMHE_@4c_Rev~$20Mil_ShareRestruc_QBuplist_MMJcultivation_OverTCntrCBDdistro_NEXT
Omni Health, Inc. Announces 3.7 Million Euro Distribution Agreement Across Europe
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
FDA_will_Approve_OMHE’s_CBD_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1
NOV/DEC2017_OMHE_PRs_Brought_PPS_from_1c_TO_4c_Next_PR_Will_Take_it_to_THE_MOON
11/14/2017 MMJ Medicine Development and Future Plans Updates News
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_@4c_Rev~$20Ml_ShareRestruc_QBuplist_MMJcultivation_OverTCntrCBDdistro_NEXT
Omni Health, Inc. Announces 3.7 Million Euro Distribution Agreement Across Europe
OMHE_with_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
Excellent find...Kraken
Welcome to the party/OMHE Board...alexah101
Welcome to the party mrgnfreeman
CheckOut_OCT2017_Message_News&LotsOfThem_AND_20Mil_Rev_were_Predicted
CLICK FOR THE MESSAGE_HERE
OMHE PPS is RUNNING to $1
OMHE_Rev~$20Mil_ShareRestruc_QBuplist_MMJcultivation_OverTCntrCBDdistro_NEXT
Omni Health, Inc. Announces 3.7 Million Euro Distribution Agreement Across Europe
SOON OMHE WILL LEAD ALL OTC STOCKS
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017 results, which they did!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed Over The Counter cannabinoid biotherapeutics/medicine
* OMHE is marketing/selling Over The Counter cannabinoid biotherapeutics/medicine to Doctor’s offices, clinics, and hospitals to ensure appropriate usage
* OMHE to Collaborate/joint venture with one of the largest European cannabis companies.
* Licensed Medical marijuana cultivation about to start.
* OMHE applied to FDA for in-house developed prescription MJ Medicine approval
* OMHE PPS is heading to $ 1 PPS
Lets_Make_OMHE_#1:OMHE_CEO_PR’d_just_TODAY_Not_Sitting_On_PR_Machine_Instead_Working_on_Big_Projects As stated in Previous_PRs. Will_Release_a_PR_at_the_RIGHT_TIMEEEEEEEEEEEEEE
OMHE_is_#4_on_MOST_POSTED_BOARDS_During_LAST_HOUR_ENOUGH_SAID
See_Proof_By_Clicking_Here
Thanks to all for your keen interest in OMHE
FACT:OMHE_Developed_CBD_Pain_Med_FDA_Approval_inProgress__NOT_ENOUGH_SAID!!!
FACT: OMHE_PPS_Rose_300%_in_LAST_4_WEEKS__Enough_Said!!!
OMHE Projected Annual Revenue=$15_to_20Million
**********OMHE's Proven Track Record Of Delivery**********
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_NON_PRESCRIPTION_CBD_MEDs_Alredy_in_use_By_Doctors_FDA_will_Approve_PRESCRIPTION_Meds_in_2018
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
FDA_will_Approve_OMHE’s_PRESCRIPTION_CBD_based_Pain_Medicine_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
OMHE_PPS_rose_from_1c_to_4c_i.e.300%_rise_in_LAST_4_WEEKS
FDA_will_Approve_OMHE's_CBD_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1
OMHE_with_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
HUGE_News_OMHE_Developed_Cannabidiol_Products_For_Largest_European_Companies
Link To News